Synthesis and bioactivities of novel 4,5,6,7-Tetrahydrothieno[2,3-c]pyridines as inhibitors of tumor necrosis factor-α (TNF-α) production
- 17 June 2002
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (12) , 1607-1611
- https://doi.org/10.1016/s0960-894x(02)00228-7
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Novel Agents Combining Platelet Activating Factor (PAF) Receptor Antagonist with Thromboxane Synthase Inhibitor (TxSI)Bioorganic & Medicinal Chemistry Letters, 2002
- Therapeutic Potential and Strategies for Inhibiting Tumor Necrosis Factor-αJournal of Medicinal Chemistry, 1999
- Anti-tnfα therapy is useful in rheumatoid arthritis and crohn’s disease: analysis of the mechanism of action predicts utility in other diseasesTransplantation Proceedings, 1998
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-α productionLife Sciences, 1997
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinNew England Journal of Medicine, 1997
- Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitorJournal of Neuroimmunology, 1997
- Anti-Tumor Necrosis Factor-α Therapy of Rheumatoid ArthritisPublished by Elsevier ,1997
- Cytokine Expression and Cell Activation in Inflammatory ArthritisPublished by Elsevier ,1996
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994